11:35 AM EDT, 05/02/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $14 to $264, reflecting 18.3x our FY 2025 (Sep.) EPS estimate, in line with BDX's historical forward average. We lift our FY 2024 adjusted EPS estimate to $13.10 from $12.94 and narrow FY 2025's to $14.40 from $14.47. Mar-Q EPS of $3.17 vs. $2.86, exceeded the S&P Capital IQ consensus estimate by $0.20 driven by strong operating margin performance on sales that were in line with market expectations. Operating margins improved 160 basis points Y/Y helped by BDX's lean management efforts, which include waste reduction and production efficiency. Given the strong quarter, BDX was able to increase its 2024 full-year adjusted EPS guidance by $0.11 at the midpoint to a range of $12.95-$13.15. We anticipate 7.5% organic sales growth in the back half of the fiscal year with almost 250 basis points contributed from Alaris and the remaining 5% growth from the rest of the BD portfolio.